Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 2Lymphoid 2Breast 2Thoracic 1Other hematologic neoplasm 1Gynecologic 1Genitourinary 1Gastrointestinal 1CNS 1

Conditions

Prostatic Neoplasms 1Lung Neoplasms 1Colorectal Neoplasms 1Breast Neoplasms 1

Interventions

pembrolizumab 182Magnetic Resonance Spectroscopy 162Specimen Handling 135enzalutamide 126Nivolumab 124Gemcitabine 99Docetaxel 96Radiosurgery 92Prednisone 85Androgen Antagonists 82Abiraterone Acetate 81Radiotherapy 75apalutamide 68Cisplatin 65darolutamide 63Ipilimumab 63Biopsy 61abiraterone 58cabozantinib 56Carboplatin 56Leuprolide 53enfortumab vedotin 50Radiation 48Pluvicto 45Standard of Care 44atezolizumab 41Surveys and Questionnaires 39acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 37X-Rays 37avelumab 35

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Chromatin Immunoprecipitation Sequencing × Genitourinary × 1 year × Clear all
NCT07291414 2026-01-21

A Self-Monitoring Platform for Tracking Medication Safety and Concerns in Cancer Patients

University of Michigan Rogel Cancer Center

Phase NA Recruiting
80 enrolled
BreastGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Lung Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡